Clinical Trial

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in relapse after allohematopoietic stem cell transplantation (AHSCT).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-02-04; most recent amendment 2026-03-10.
Status change: Recruiting → Active, Not Recruiting 2026-03-10
Status change: Not Yet Recruiting → Recruiting 2023-04-06
Trial Details
NCT Number NCT05226455
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: AbbVie
Conditions MDS, AML
Enrollment 55 participants
Start Date 2022-11-23
Primary Completion 2026-11-15 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12